Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women
Brief Summary: The purpose of this study was to evaluate the safety, efficacy, and immunogenicity of V503 in comparison to GARDASIL. The primary hypotheses tested in the study were 1) V503 administered to 16- to 26-year-old adolescents and young women is generally well-tolerated, 2) V503 reduces combined incidence of Human Papillomavirus (HPV) Type 31/33/45/52/58-related disease compared with GARDASIL, and 3) V503 induces non-inferior geometric mean titers for HPV Type 6/11/16/18 antibodies compared with GARDASIL.


Options:
A: Arm Label: Cervarix 2 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Drug: Placebo | Arm Label: Gardasil 2 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Gardasil, Drug: Placebo | Arm Label: Gardasil 3 dose Group; Type: EXPERIMENTAL; Interventions: Biological: Gardasil | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix 2 dose Group | Intervention Type: BIOLOGICAL; Name: Gardasil; Assigned to Arm(s): Gardasil 2 dose Group, Gardasil 3 dose Group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cervarix 2 dose Group, Gardasil 2 dose Group
B: Arm Label: Arm A: QHPV; Type: ACTIVE_COMPARATOR; Interventions: Biological: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV) | Arm Label: Arm B: Placebo/QHPV; Type: OTHER; Interventions: Other: Placebo/QHPV | Intervention Type: BIOLOGICAL; Name: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV); Assigned to Arm(s): Arm A: QHPV | Intervention Type: OTHER; Name: Placebo/QHPV; Assigned to Arm(s): Arm B: Placebo/QHPV
C: Arm Label: Low-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: Mid-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: High-dose V503; Type: EXPERIMENTAL; Interventions: Biological: Experimental: V503 | Arm Label: Gardasil; Type: ACTIVE_COMPARATOR; Interventions: Biological: Comparator: GARDASIL, Biological: Experimental: V503 | Intervention Type: BIOLOGICAL; Name: Comparator: GARDASIL; Assigned to Arm(s): Gardasil | Intervention Type: BIOLOGICAL; Name: Experimental: V503; Assigned to Arm(s): Gardasil, High-dose V503, Low-dose V503, Mid-dose V503
D: Arm Label: Girls 9 to 14 Years V503 at Months 0 and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Boys 9 to 14 Years V503 at Months 0 and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Girls and Boys 9 to 14 Years V503 at Months 0 and 12; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Girls 9 to 14 Years V503 at Months 0, 2, and 6; Type: EXPERIMENTAL; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Arm Label: Young Women 16 to 26 Years V503 at Months 0, 2, and 6; Type: ACTIVE_COMPARATOR; Interventions: Biological: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine) | Intervention Type: BIOLOGICAL; Name: V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine); Assigned to Arm(s): Boys 9 to 14 Years V503 at Months 0 and 6, Girls 9 to 14 Years V503 at Months 0 and 6, Girls 9 to 14 Years V503 at Months 0, 2, and 6, Girls and Boys 9 to 14 Years V503 at Months 0 and 12, Young Women 16 to 26 Years V503 at Months 0, 2, and 6

Answer: C